SCHEMBL24944427

SCHEMBL24944427

CNc1nc(Nc2ccc(CN3CCC(F)(F)C3)cc2)c(C(N)=O)nc1-c1cncc2c1ncn2C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNC P24863 1/20 0.38
▸ CDK8 P49336 1/20 0.38
▸ GRM2 Q14416 3/20 0.36
▸ MELK Q14680 1/20 0.35
▸ IKBKE Q14164 1/20 0.34
▸ TBK1 Q9UHD2 1/20 0.34
▸ WNT1 P04628 3/20 0.34
▸ DYRK1A Q13627 3/20 0.34
▸ CLK2 P49760 2/20 0.34
▸ CLK3 P49761 2/20 0.34
▸ SYK P43405 4/20 0.33
▸ PRKAA2 P54646 1/20 0.33
▸ TLR7 Q9NYK1 2/20 0.32
▸ PDGFRA P16234 1/20 0.32
▸ PDCD1 Q15116 1/20 0.32
▸ CD274 Q9NZQ7 1/20 0.32
▸ EML4 Q9HC35 1/20 0.32
▸ ALK Q9UM73 1/20 0.32
▸ JAK2 O60674 1/20 0.32
▸ JAK1 P23458 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL30205548 0.97 CCNC (0.38) CCNCCDK8GRM2MELKIKBKE
Formic Acid SCHEMBL29173318 0.97 CCNC (0.38) CCNCCDK8GRM2MELKIKBKE
SCHEMBL24944172 0.89 TBK1 (0.39) CCNCCDK8MELKIKBKETBK1
SCHEMBL24943840 0.88 IKBKE (0.46) MELKIKBKETBK1SYKEML4
SCHEMBL30205589 0.88 IKBKE (0.46) MELKIKBKETBK1SYKEML4
SCHEMBL24944183 0.87 SYK (0.44) CCNCCDK8SYKPDGFRAEML4
SCHEMBL30205579 0.87 SYK (0.44) CCNCCDK8SYKPDGFRAEML4
SCHEMBL30801879 0.86 IKBKE (0.35) CCNCCDK8IKBKETBK1SYK
SCHEMBL24944188 0.86 IKBKE (0.35) CCNCCDK8IKBKETBK1SYK
SCHEMBL24944443 0.86 EML4 (0.36) GRM2IKBKETBK1SYKPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed
Send feedback